BIOMAT Database Logo BIOMAT Database Logo

Evidence that anti-asialo GM1 in vivo improves engraftment of T cell-depleted bone marrow in hybrid recipients. 1990

J L Ferrara, and P Mauch, and P J Van Dijken, and K E Crosier, and J Michaelson, and S J Burakoff
Division of Pediatric Hematology/Oncology, Children's Hospital, Boston, MA 02115.

Engraftment of T cell-depleted bone marrow was studied in a P----F1 murine bone marrow transplant model which features long-term stability of mixed chimerism of donor (B6) and host (B6AF1) cells after BMT. We report that a polyclonal antibody to asialo GM1 (anti-ASGM1) given in vivo after transplant was able to increase long-term donor bone marrow engraftment. In vivo anti-ASGM1 eliminated NK activity but did not affect the generation of cytotoxic T cells nor did it stimulate hematopoiesis in vitro. Anti-Thy 1.2, a pan-T cell monoclonal antibody, had no effect on donor engraftment. We conclude that ASGM1+ cells with NK activity inhibit the long-term engraftment of bone marrow stem cells in this model and that antibodies to NK cells can be used in vivo as an effective component of the transplant conditioning regimen.

UI MeSH Term Description Entries
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D005677 G(M1) Ganglioside A specific monosialoganglioside that accumulates abnormally within the nervous system due to a deficiency of GM1-b-galactosidase, resulting in GM1 gangliosidosis. GM1 Ganglioside,Monosialosyl Tetraglycosyl Ceramide,GM1a Monosialoganglioside,Ceramide, Monosialosyl Tetraglycosyl,Ganglioside, GM1,Monosialoganglioside, GM1a,Tetraglycosyl Ceramide, Monosialosyl
D006028 Glycosphingolipids Lipids containing at least one monosaccharide residue and either a sphingoid or a ceramide (CERAMIDES). They are subdivided into NEUTRAL GLYCOSPHINGOLIPIDS comprising monoglycosyl- and oligoglycosylsphingoids and monoglycosyl- and oligoglycosylceramides; and ACIDIC GLYCOSPHINGOLIPIDS which comprises sialosylglycosylsphingolipids (GANGLIOSIDES); SULFOGLYCOSPHINGOLIPIDS (formerly known as sulfatides), glycuronoglycosphingolipids, and phospho- and phosphonoglycosphingolipids. (From IUPAC's webpage) Asialoganglioside,Asialogangliosides,Glycosphingolipid,Sphingoglycolipid,Sphingoglycolipids
D006410 Hematopoiesis The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY). Hematopoiesis, Medullary,Haematopoiesis,Medullary Hematopoiesis
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000906 Antibodies Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte

Related Publications

J L Ferrara, and P Mauch, and P J Van Dijken, and K E Crosier, and J Michaelson, and S J Burakoff
CD34 augmentation improves allogeneic T cell-depleted bone marrow engraftment.
April 1998, Journal of hematotherapy,
J L Ferrara, and P Mauch, and P J Van Dijken, and K E Crosier, and J Michaelson, and S J Burakoff
Anti-asialo GM1 antiserum treatment of lethally irradiated recipients before bone marrow transplantation: evidence that recipient natural killer depletion enhances survival, engraftment, and hematopoietic recovery.
October 1990, Blood,
J L Ferrara, and P Mauch, and P J Van Dijken, and K E Crosier, and J Michaelson, and S J Burakoff
Engraftment of T-cell-depleted rabbit bone marrow.
January 1987, Acta haematologica,
J L Ferrara, and P Mauch, and P J Van Dijken, and K E Crosier, and J Michaelson, and S J Burakoff
Effect of rabbit anti-asialo GM1 treatment in vivo or with anti-asialo GM1 plus complement in vitro on cytotoxic T cell activities.
June 1986, Journal of immunology (Baltimore, Md. : 1950),
J L Ferrara, and P Mauch, and P J Van Dijken, and K E Crosier, and J Michaelson, and S J Burakoff
Engraftment of T-cell-depleted bone marrow in murine models for allogeneic bone marrow transplantation.
January 1990, Cancer treatment and research,
J L Ferrara, and P Mauch, and P J Van Dijken, and K E Crosier, and J Michaelson, and S J Burakoff
Transient engraftment of T cell-depleted allogeneic bone marrow in mice improves survival rate following lethal irradiation.
March 1988, Bone marrow transplantation,
J L Ferrara, and P Mauch, and P J Van Dijken, and K E Crosier, and J Michaelson, and S J Burakoff
A correlation between conditioning and engraftment in recipients of MHC-mismatched T cell-depleted murine bone marrow transplants.
August 1985, Journal of immunology (Baltimore, Md. : 1950),
J L Ferrara, and P Mauch, and P J Van Dijken, and K E Crosier, and J Michaelson, and S J Burakoff
Suppressive activity in recipients of non-T cell-depleted allogeneic bone marrow transplants: role of T cell-depleted syngeneic marrow.
December 1989, Bone marrow transplantation,
J L Ferrara, and P Mauch, and P J Van Dijken, and K E Crosier, and J Michaelson, and S J Burakoff
Cytomegalovirus pneumonia prior to engraftment following T-cell depleted bone marrow transplantation.
January 1994, Medical oncology (Northwood, London, England),
J L Ferrara, and P Mauch, and P J Van Dijken, and K E Crosier, and J Michaelson, and S J Burakoff
In vivo administration of anti-CD3 monoclonal antibodies or immunotoxins in murine recipients of allogeneic T cell-depleted marrow for the promotion of engraftment.
September 1991, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!